Stuart Milstein

This inventor holds 94 USPTO granted patents and 51 published patent applications, plus 11 CIPO patents and 17 EPO patents, primarily in RNA Interference (CPC class C12N2310-14). Top assignees: Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Novartis Ag. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stuart Milstein. Retrieved from https://idiyas.com/inventor/stuart-milstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 94 (Patent Applications = 51)

% Patents Active = 92.6

CIPO Patents = 11 (Patent Applications = 24)

EPO Patents = 17 (Patent Applications = 63)

Average Co-Inventor Count = 7.2

ph-index = 13

Forward Citations = 428(Granted Patents)

Forward Citations (Not Self Cited) = 245(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Cambridge, MA (US) (2012 - 2024)
Arlington, MA (US) (2016 - 2024)

Company Filing History:

70 out of 466

Alnylam Pharmaceuticals, Inc.

patents

12 out of 102

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

patents

5. 2 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

iRNA Compositions

ANGPTL3

PCSK9

Hepatitis B

Modified RNA Agents

Extrahepatic Delivery

Superoxide Dismutase

Transthyretin

Organic Compositions

Neurodegenerative Diseases

HSD17B13

Apolipoprotein C3

94 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50996 - SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF (2026-08-18),

2. 12655430 - HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF (2026-06-16),

3. 12565653 - ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof (2026-03-03),

4. 12467051 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2025-11-11),

5. 12460206 - PCSK9 iRNA compositions and methods of use thereof (2025-11-04),

6. 12397013 - Extrahepatic delivery (2025-08-26),

7. 12385044 - Modified double-stranded RNA agents (2025-08-12),

8. 12385043 - Modified double-stranded RNA agents (2025-08-12),

9. 12378553 - Modified double-stranded RNA agents (2025-08-05),

10. 12359201 - 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof (2025-07-15),

11. 12227744 - Compositions and methods for inhibiting expression of transthyretin (2025-02-18),

12. 12173289 - Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof (2024-12-24),

13. 12168767 - Modified double-stranded RNA agents (2024-12-17),

14. 12091661 - Organic compositions to treat HSF1-related diseases (2024-09-17),

15. 12005074 - Extrahepatic delivery (2024-06-11),

Title: The Innovative Journey of Stuart Milstein

Introduction: Stuart Milstein, a visionary inventor based in Cambridge, MA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Stuart Milstein holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a background in engineering and a passion for problem-solving, Stuart Milstein has led successful projects that have revolutionized industries and improved the lives of many. His commitment to innovation is evident in the numerous patents he has secured over the years.

Collaborations: Stuart Milstein has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Stuart Milstein's relentless pursuit of innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the world of inventions. His impact on various industries is profound, and his legacy as an inventor continues to inspire future generations of innovators.

Profile summary based on public USPTO records.